GSDMB overexpression associates with advanced disease or poor prognosis in breast, oral and gastric cancer (Nguyen et al., 2007; Komiyama et al., 2010; Hergueta-Redondo et al., 2014, 2016), and increases invasive and/or metastatic behavior in breast and bladder cancer cells (Hergueta-Redondo et al., 2014; Molina-Crespo et al., 2019; He et al., 2021). Here, GSDMB is linked to gastric cancer.